RecruitingPhase 1NCT06772753

Investigation of Psychedelic Effects in Psychoactive Substances


Sponsor

Johns Hopkins University

Enrollment

50 participants

Start Date

Feb 5, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The aim of this double-blind, placebo-controlled, within-subjects study is to determine whether other psychoactive substances can produce experiences akin to those seen with classic psychedelics. Screening involves a medical and psychiatric examination, including blood draw, history and physical, interviews, and questionnaires. Eligible participants will then be asked to complete up to 6 experimental drug administration session during which the participants will potentially receive and report on the subjective effects of 6 different psychoactive substances or inactive placebo. Drug assignment for some sessions will be randomized (like flipping a count or rolling a pair of dice), and both participants and study staff will be blind to the drug condition on any given day. Participants will also complete 2 preparation sessions (4 hours total) before the first experimental session, and follow-up visits after each session to discuss and debrief on the participants subjective experience.


Eligibility

Min Age: 25 YearsMax Age: 55 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Dextromethorphan (DXM), a drug called Dimethyltryptamine (DMT), and others for people with psychedelic effects in healthy volunteers. The study is currently recruiting participants at 1 location. People eligible for this study include aged 25 Years to 55 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGPlacebo

inactive substance

DRUGPsilocybin

active comparator for psychedelic effects

DRUGKetamine

psychoactive substance

DRUGDextromethorphan (DXM)

psychoactive substance

DRUGDimethyltryptamine (DMT)

psychoactive substance

DRUGMethylenedioxymethamphetamine (MDMA)

psychoactive substance

DRUGTetrahydrocannabinol (THC)

psychoactive substance


Locations(1)

Johns Hopkins Center for Psychedelic and Consciousness Research

Baltimore, Maryland, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06772753


Related Trials